The Annals Take our Readership Survey!
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

The Annals of Pharmacotherapy: Vol. 37, No. 1, pp. 116-121. DOI 10.1345/aph.1C101
© 2003 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nowak, S. N
Right arrow Articles by Jaber, L. A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nowak, S. N
Right arrow Articles by Jaber, L. A

DRUG INFORMATION ROUNDS

Aspirin Dose for Prevention of Cardiovascular Disease in Diabetics

Sandra N Nowak, PharmD

Postdoctoral Research Fellow, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI

Linda A Jaber, PharmD

Associate Professor, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University

Reprints: Linda A Jaber PharmD, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, 259 Mack Ave., Detroit, MI 48201, FAX 313/577-5369, E-mail ljaber{at}wayne.edu

OBJECTIVE: To determine whether a specific dose of aspirin can be recommended for prevention of cardiovascular disease in patients with diabetes.

DATA SOURCE: Biomedical literature was accessed through MEDLINE (1990–February 2002). Key terms included diabetes, cardiovascular protection, and aspirin.

DATA SYNTHESIS: Pharmacologic and clinical studies focusing on the dose–response relationship of aspirin therapy were reviewed. Evidence supports the benefit of low-dose aspirin therapy in reducing vascular events in secondary and primary prevention trials in various patient populations; however, some studies suggest larger doses of aspirin may be needed in certain patients.

CONCLUSIONS: Review of the evidence does not support a particular dose of aspirin for cardiovascular protection in diabetic patients. Clinical guidelines recommend aspirin therapy in the range of 81–325 mg/d. However, due to an increased prevalence of cardiovascular morbidity and disturbances in coagulation in diabetic patients, the dose of aspirin for prevention of cardiovascular disease in these individuals may be different from that in other populations and requires further evaluation.

Key Words: aspirin, cardiovascular protection, diabetes

www.theannals.com, DOI


This article has been cited by other articles:


Home page
 J. Am. Soc. Nephrol.Home page
M. Trovati and F. Cavalot
Optimization of Hypolipidemic and Antiplatelet Treatment in the Diabetic Patient with Renal Disease
J. Am. Soc. Nephrol., January 1, 2004; 15(90010): S12 - 20.
[Abstract] [Full Text]


homecopy help contact us subscription past issues search current issue
Copyright © 2003 by Harvey Whitney Books Company.